News

Perfecseal's high-barrier PVC-free blister-forming web, PerfecForm SkyBlue, is based on polyolefin chemistry, and its new high-barrier flow-wrap specification, PerfecPharm P232, is capable of achieving hermetic seals at the maximum speed capabilities of the top flow-wrap equipment.

Pfizer has announced plans to internally separate its commercial operations into three business segments.

Depomed, Inc. announced that FDA has accepted for filing a new drug application (NDA) from Mallinckrodt for MNK-795.

Aesica has appointed Chris Gowland as Chief Operating Officer, a new position created to further enhance the company's operational performance in APIs and formulated product manufacturing services.

Scientists at A*STAR's Genome Institute of Singapore (GIS) have identified genes that could be potential targets for anticancer agents in the treatment of aggressive breast cancer.

Kemwell Biopharma announced that it has acquired Cirrus Pharmaceuticals Inc., a contract development services company based in Research Triangle Park, N.C.

Australian team develops method for making ultrafine particles for more efficient drug delivery.

Adaptimmune has opened a Phase I/IIa ovarian cancer trial to evaluate its genetically engineered T cell treatment, with enhanced antitumor activity.

The report highlights a need for greater third party certification to ensure GMP vigilance.

The Muller Group has appointed Dr Christian Heuer as new chief operating officer of Müller AG Cleaning Solutions.

Aptuit has announced that Maurizio Denaro has assumed responsibilities as general manager of The Aptuit Center for Discovery & Development in Verona, Italy.

Galectin Therapeutics has submitted a Fast Track application to the FDA to help expedite its clinical development program.

Charles River has established partnerships with Target Health Inc. and Theorem Clinical Research Inc.

Zeiss announced the acquisition of U.S.-based Xradia, Inc.

FDA conducted a general inspection of operations and quality systems of Albany Molecular Research Inc (AMRI) in Burlington, Mass.

Abbott announces earnings per share above previous guidance range and notes increased sales in emerging markets.

Acquisition database helps extend product lifecycle by seeking new applications for drugs.

Life Technologies Corporation has filed a definitive proxy statement with the US Securities and Exchange Commission regarding Thermo Fisher Scientific Inc.

UK government review will look for unnecessary regulatory burdens and inconsistencies and at guidance clarity.

Bashir Hansraj appointed as Global Technical Director, and David Ross and Sven Thomas appointed as business development managers

Molecular Profiles has opened a new clinical manufacturing facility following a successful inspection from the Medicines and Healthcare products Regulatory Agency.

Penn Pharma has announced plans to invest in additional tablet manufacturing and coating capacity.

13 full members with expertise across the entire pharmaceutical supply chain.

Almac's Clinical Services business unit has expanded its service offering for dispensing and bottling solid dosage products.

The precautionary recall follows manufacturing deficiencies identified at the site in India.

Vetter has ready-to-submit documentation for this service in Common Technical Document (CTD) formats for the US, Europe and Japan.

Molecular Profiles has opened a new facility in the UK following official approval from MHRA.

The new ink takes less a second to dry and is four times more fade resistant than inks that are typically used in retail packaging.

The facility, which includes state-of-the-art formulation, analytical and synthetic laboratories as well as a customer training center, will focus on bioavailability enhancement and oral dosage formulations.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.